What this Trial Is About

Researchers are investigating elevated homocysteine levels in the blood of patients with Parkinson's disease who are currently treated with levodopa. The study aims to evaluate whether open label B vitamin therapy can correct elevated homocysteine and to understand how homocysteine levels affect cognitive function in these patients. This pilot study focuses on participants aged 40 to 90 years with Parkinson's disease meeting specific clinical criteria. Participants will take daily supplements of folic acid (1 mg), vitamin B6 (25 mg), and vitamin B12 (1,000 ug) as part of the open label homocysteine management therapy. The study monitors homocysteine and B vitamin deficiency levels at baseline to assess treatment impact. The intervention involves dietary supplements given daily, with the goal of correcting elevated homocysteine associated with levodopa treatment. Throughout the study, participants will undergo cognitive assessments including the Montreal Cognitive Assessment (MOCA) and laboratory tests to measure homocysteine and kidney function (glomerular filtration rate). Researchers will evaluate the ability to provide informed consent and monitor blood pressure and insulin use history to ensure safety. The study focuses on the relationship between homocysteine management and cognitive function during the treatment period.

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease